CN113528572A - 一种小鼠早衰模型及其构建方法与应用 - Google Patents
一种小鼠早衰模型及其构建方法与应用 Download PDFInfo
- Publication number
- CN113528572A CN113528572A CN202110842679.9A CN202110842679A CN113528572A CN 113528572 A CN113528572 A CN 113528572A CN 202110842679 A CN202110842679 A CN 202110842679A CN 113528572 A CN113528572 A CN 113528572A
- Authority
- CN
- China
- Prior art keywords
- mouse
- hbxip
- model
- lysm
- cre
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000002028 premature Effects 0.000 title claims abstract description 27
- 238000010276 construction Methods 0.000 title abstract description 8
- 241000699666 Mus <mouse, genus> Species 0.000 claims abstract description 93
- 101001017961 Homo sapiens Ragulator complex protein LAMTOR5 Proteins 0.000 claims abstract description 68
- 102100033373 Ragulator complex protein LAMTOR5 Human genes 0.000 claims abstract description 66
- 241000699670 Mus sp. Species 0.000 claims abstract description 44
- 238000000034 method Methods 0.000 claims abstract description 24
- 210000004027 cell Anatomy 0.000 claims abstract description 13
- 102000021127 protein binding proteins Human genes 0.000 claims abstract description 10
- 230000014509 gene expression Effects 0.000 claims abstract description 9
- 108700025184 hepatitis B virus X Proteins 0.000 claims abstract description 9
- 238000012216 screening Methods 0.000 claims abstract description 6
- 230000002265 prevention Effects 0.000 claims abstract description 3
- 108090000623 proteins and genes Proteins 0.000 claims description 26
- 239000002773 nucleotide Substances 0.000 claims description 14
- 125000003729 nucleotide group Chemical group 0.000 claims description 14
- 238000010172 mouse model Methods 0.000 claims description 11
- 230000013011 mating Effects 0.000 claims description 10
- 206010063493 Premature ageing Diseases 0.000 claims description 7
- 208000032038 Premature aging Diseases 0.000 claims description 7
- 108010051219 Cre recombinase Proteins 0.000 claims description 6
- 210000002798 bone marrow cell Anatomy 0.000 claims description 6
- 238000011161 development Methods 0.000 claims description 5
- 230000018109 developmental process Effects 0.000 claims description 5
- 238000011740 C57BL/6 mouse Methods 0.000 claims description 4
- 108020004999 messenger RNA Proteins 0.000 claims description 3
- 241000700721 Hepatitis B virus Species 0.000 claims description 2
- 101710086987 X protein Proteins 0.000 claims 1
- 230000032683 aging Effects 0.000 abstract description 29
- 210000002966 serum Anatomy 0.000 abstract description 15
- 230000009758 senescence Effects 0.000 abstract description 14
- 238000011160 research Methods 0.000 abstract description 6
- 201000010099 disease Diseases 0.000 abstract description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 5
- 238000005516 engineering process Methods 0.000 abstract description 5
- 239000000463 material Substances 0.000 abstract description 5
- 210000001185 bone marrow Anatomy 0.000 abstract description 3
- 239000003814 drug Substances 0.000 abstract description 3
- 229940079593 drug Drugs 0.000 abstract description 3
- 235000013305 food Nutrition 0.000 abstract description 3
- 230000003827 upregulation Effects 0.000 abstract description 3
- 230000005784 autoimmunity Effects 0.000 abstract description 2
- 230000035617 depilation Effects 0.000 abstract description 2
- 238000003745 diagnosis Methods 0.000 abstract description 2
- 210000002865 immune cell Anatomy 0.000 abstract description 2
- 230000001939 inductive effect Effects 0.000 abstract description 2
- 208000027866 inflammatory disease Diseases 0.000 abstract description 2
- 208000030159 metabolic disease Diseases 0.000 abstract description 2
- 230000004770 neurodegeneration Effects 0.000 abstract description 2
- 208000015122 neurodegenerative disease Diseases 0.000 abstract description 2
- 210000000056 organ Anatomy 0.000 abstract description 2
- 230000008506 pathogenesis Effects 0.000 abstract description 2
- 238000012827 research and development Methods 0.000 abstract description 2
- 230000003248 secreting effect Effects 0.000 abstract description 2
- 210000001519 tissue Anatomy 0.000 abstract description 2
- 230000000694 effects Effects 0.000 description 18
- 238000001514 detection method Methods 0.000 description 12
- 235000018102 proteins Nutrition 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 description 8
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 8
- 108010082126 Alanine transaminase Proteins 0.000 description 8
- 108090000143 Mouse Proteins Proteins 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 7
- 241001529936 Murinae Species 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 6
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 6
- 210000001541 thymus gland Anatomy 0.000 description 6
- 241000699660 Mus musculus Species 0.000 description 5
- 238000011529 RT qPCR Methods 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 210000002700 urine Anatomy 0.000 description 5
- KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical compound OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 108020005004 Guide RNA Proteins 0.000 description 4
- 210000004979 bone marrow derived macrophage Anatomy 0.000 description 4
- 238000009395 breeding Methods 0.000 description 4
- 230000001488 breeding effect Effects 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 230000003908 liver function Effects 0.000 description 4
- 210000000066 myeloid cell Anatomy 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 241000581650 Ivesia Species 0.000 description 3
- 230000003907 kidney function Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 238000000465 moulding Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000010200 validation analysis Methods 0.000 description 3
- 238000012795 verification Methods 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- HORQAOAYAYGIBM-UHFFFAOYSA-N 2,4-dinitrophenylhydrazine Chemical compound NNC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O HORQAOAYAYGIBM-UHFFFAOYSA-N 0.000 description 2
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 2
- 102100022900 Actin, cytoplasmic 1 Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 238000009010 Bradford assay Methods 0.000 description 2
- 108091033409 CRISPR Proteins 0.000 description 2
- 108010067770 Endopeptidase K Proteins 0.000 description 2
- 102000003777 Interleukin-1 beta Human genes 0.000 description 2
- 108090000193 Interleukin-1 beta Proteins 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 2
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 2
- 238000010818 SYBR green PCR Master Mix Methods 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 108090000340 Transaminases Proteins 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- HWXBTNAVRSUOJR-UHFFFAOYSA-N alpha-hydroxyglutaric acid Natural products OC(=O)C(O)CCC(O)=O HWXBTNAVRSUOJR-UHFFFAOYSA-N 0.000 description 2
- 229940009533 alpha-ketoglutaric acid Drugs 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 230000005251 gamma ray Effects 0.000 description 2
- 210000003714 granulocyte Anatomy 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 229940076788 pyruvate Drugs 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 102000014898 transaminase activity proteins Human genes 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 238000009423 ventilation Methods 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 1
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 1
- 238000010354 CRISPR gene editing Methods 0.000 description 1
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 1
- 101710150820 Cellular tumor antigen p53 Proteins 0.000 description 1
- 102000016736 Cyclin Human genes 0.000 description 1
- 108050006400 Cyclin Proteins 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 230000008265 DNA repair mechanism Effects 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 102000012199 E3 ubiquitin-protein ligase Mdm2 Human genes 0.000 description 1
- 108050002772 E3 ubiquitin-protein ligase Mdm2 Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 208000037487 Endotoxemia Diseases 0.000 description 1
- 241000282414 Homo sapiens Species 0.000 description 1
- 101000891649 Homo sapiens Transcription elongation factor A protein-like 1 Proteins 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000008135 Mechanistic Target of Rapamycin Complex 1 Human genes 0.000 description 1
- 108010035196 Mechanistic Target of Rapamycin Complex 1 Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101000596402 Mus musculus Neuronal vesicle trafficking-associated protein 1 Proteins 0.000 description 1
- 101000800539 Mus musculus Translationally-controlled tumor protein Proteins 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 101000781972 Schizosaccharomyces pombe (strain 972 / ATCC 24843) Protein wos2 Proteins 0.000 description 1
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 1
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 1
- 101001009610 Toxoplasma gondii Dense granule protein 5 Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 206010069351 acute lung injury Diseases 0.000 description 1
- GZCGUPFRVQAUEE-KCDKBNATSA-N aldehydo-D-galactose Chemical compound OC[C@@H](O)[C@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-KCDKBNATSA-N 0.000 description 1
- 230000001195 anabolic effect Effects 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000004900 autophagic degradation Effects 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000008049 biological aging Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 210000001163 endosome Anatomy 0.000 description 1
- 230000007159 enucleation Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000012224 gene deletion Methods 0.000 description 1
- 238000003209 gene knockout Methods 0.000 description 1
- 238000003205 genotyping method Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 238000001746 injection moulding Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000002132 lysosomal effect Effects 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 230000032696 parturition Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000000751 protein extraction Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 210000005084 renal tissue Anatomy 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000012192 staining solution Substances 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0276—Knock-out vertebrates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Environmental Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Plant Pathology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
本发明公开了一种小鼠早衰模型及其构建方法与应用,所述小鼠早衰模型是通过敲除小鼠骨髓来源细胞中的乙肝病毒X蛋白结合蛋白而获得的。该早衰小鼠在4‑8个月龄时出现脱毛、衰老相关基因表达显著上调、血清中衰老相关的分泌表型因子上调、组织器官衰老等典型的早衰表型。本发明通过操控骨髓来源的免疫细胞条件性敲除HBXIP,诱导小鼠早衰具有显著的创新性和良好的应用前景,可用于建立延缓衰老的个性化药物/食材/技术方法等的筛选平台,同时,可用于研究衰老相关疾病,如神经退行性疾病、代谢性疾病、自身免疫及炎症性疾病等发病机制研究,以及相关疾病的预防、诊断和治疗等技术和产品研发。
Description
技术领域
本发明涉及生物技术领域中,具体涉及一种小鼠早衰模型及其构建方法与应用。
背景技术
早衰即过早衰老,是指由于各种内在的或外在的原因使机体过早地出现生理上、体质上和心理上衰弱的现象,且其病理机制尚未明确。因此,衰老相关疾病已成为全球科研领域亟需解决和突破的热点及难点,延缓衰老是保证社会稳定、经济持续性发展的必要条件。
利用小鼠等模式生物衰老模型能更好地认识人类衰老的进程,为临床转化研究提供有效的工具和理论基础。常见的小鼠衰老模型主要包括D-半乳糖小鼠衰老模型、γ射线照射诱导小鼠衰老模型、胸腺摘除诱导小鼠衰老模型。除自然衰老小鼠模型以外,目前常见的小鼠衰老模型主要包括D-半乳糖注射小鼠衰老模型、胸腺摘除诱导小鼠衰老模型、γ射线照射诱导小鼠衰老模型等,这三种常见的小鼠衰老模型的构建方法及存在的缺陷如下所述:1)D-半乳糖注射法小鼠衰老模型:小鼠腹腔注射D-半乳糖生理盐水溶液500毫克/千克/天,连续2个月成模。每天注射D-半乳糖比较繁琐,注射造模时间较长,需要2个月左右,且由于小鼠的个性差异较大,不易控制;2)胸腺摘除小鼠衰老模型:麻醉小鼠,剥离并取出胸腺,缝合切口并滴加青霉素,继续常规饲养6个月成模。该造模方法对试验技术要求较高,在摘除胸腺时容易导致小鼠死亡,有一定的差异性。其耗费时间更长,需要6个月。胸腺摘除小鼠,对于衰老的某些免疫指标无法进行定性或定量的测定,难以判断是否达到理想的衰老状态,影响模型的可信度;3)γ射线照射诱导小鼠衰老模型:小鼠给予3Gy全身照射(照射面积为25cm×25cm,高度为80cm,时间为5min),每10天一次,共8次,总计24Gy,80天后成模型。但是如果辐射剂量过大,则会使试验动物容易死亡,无法进行试验,因此要掌握好辐射的度和时间。
乙肝病毒X蛋白结合蛋白(hepatitis B X-interacting protein,HBXIP),是一种主要存在于哺乳动物的细胞组成型蛋白,分子量约为19kDa。HBXIP能够抑制乙型肝炎病毒的复制,促进肿瘤细胞的增殖和迁移,抑制LPS诱导的急性肺损伤和内毒素血症等。研究表明HBXIP促进细胞周期蛋白上调,抑制细胞周期负调控因子p21、p27表达,从而促进细胞增殖。HBXIP通过MDM2促进肿瘤抑制因子p53的降解,加速乳腺癌的生长。此外,HBXIP是晚期内体/溶酶体适配器以及MAPK和哺乳动物雷帕霉素靶蛋白LAMTOR复合物的成员之一,参与调控mTORC1的活化,影响细胞的合成代谢、翻译、转录、脂质合成、自噬等过程。因此,HBXIP是参与机体重要生命活动的调节因子。本发明提供了一种基于HBXIP条件敲除的小鼠早衰模型构建及相关应用。
发明内容
发明目的:本发明所要解决的技术问题是针对现有技术的不足,提供一种小鼠早衰模型。
本发明还要解决的技术问题是提供上述小鼠早衰模型的构建方法。
本发明最后要解决的技术问题是提供上述小鼠早衰模型的应用。
为了解决上述第一个技术问题,本发明公开了一种小鼠早衰模型,其特征在于,敲除小鼠骨髓来源细胞中的乙肝病毒X蛋白结合蛋白(HBXIP)。
其中,所述敲除为敲除乙肝病毒X蛋白结合蛋白编码基因中的第二个外显子。
其中,所述乙肝病毒X蛋白结合蛋白编码基因的mRNA序列为Gene Bank中的Accession:NM_026774.2,其基因组序列为Gene Bank中的Accession:NC_000069.7。
其中,所述敲除为通过Cre-loxp系统敲除;优选地,所述敲除为通过骨髓细胞特异性表达Cre重组酶小鼠LysMcre/+敲除。
为了解决上述第二个技术问题,本发明公开了上述小鼠早衰模型的构建方法,包括如下步骤:
(1)将HBXIPfl/+小鼠与HBXIPfl/+小鼠交配,获得HBXIPfl/fl纯合子小鼠;
(2)将HBXIPfl/fl小鼠与LysMcre/+小鼠交配,获得BXIPfl/+-LysMcre/+小鼠;
(3)将HBXIPfl/+-LysMcre/+小鼠与HBXIPfl/+-LysMcre/+小鼠交配,获得HBXIPfl/fl-LysMcre/+小鼠(HBXIP△LysM)。
步骤(1)中,所述HBXIPfl/+小鼠为将C57BL/6小鼠中乙肝病毒X蛋白结合蛋白基因组(NC_000069.7)的第二个外显子(1013-1074)两侧的内含子区域分别添加loxp1位点和loxp2位点,即在HBXIP基因组序列的第762位核苷酸后插入如SEQ ID No.1所示的核苷酸序列(loxp1位点),第1250位核苷酸后插入如SEQ ID No.2所示的核苷酸序列(loxp2位点)。
其中,所述loxp序列的插入方法可以用多种已知的、被大家公认的方法获得。
为了解决上述第三个技术问题,本发明公开了上述小鼠早衰模型的应用。
其中,所述应用为所述小鼠早衰模型在开发或筛选预防和/或治疗早衰产品中的应用;其中,所述产品包括但不限于药物、食品、保健品、化妆品。
其中,所述应用为所述小鼠早衰模型在开发或筛选预防和/或治疗早衰技术方法中的应用。
其中,所述应用为所述小鼠早衰模型在早衰研究中的应用。
有益效果:与现有技术相比,本发明具有如下优势:
(1)本发明中,所述早衰小鼠在4-8个月龄时出现脱毛、衰老相关基因表达显著上调、血清中衰老相关的分泌表型因子上调、组织器官衰老等典型的早衰表型。
(2)对比自然衰老小鼠(18-24月龄),本发明所提供的髓系细胞条件性敲除HBXIP小鼠具有饲养周期短(6-8月龄)、个体差异小、干扰因素少、成本低等优势。
(3)对比目前常见的三种小鼠衰老模型,本发明所提供的髓系细胞条件性敲除HBXIP小鼠早衰模型具有1)无需繁杂的造模过程,可稳定繁殖,自发衰老表型;2)对实验技术要求不高且易于控制,可避免造模过程中因操作等原因所导致的小鼠死亡;3)衰老状态易于检测和表征,可准确判断小鼠的衰老状态,模型可信度高;4)基因敲除背景小鼠个体差异小等优势;5)且髓系细胞条件性HBXIP敲除,是指HBXIP的敲除具有细胞特异性,仅在骨髓细胞系中发生,包括单核细胞、成熟的巨噬细胞和粒细胞等。
(4)本发明通过操控骨髓来源的免疫细胞条件性敲除HBXIP,诱导小鼠早衰具有显著的创新性和良好的应用前景,可用于建立延缓衰老的个性化药物/食材/技术方法等的筛选平台,同时,可用于研究衰老相关疾病,如神经退行性疾病、代谢性疾病、自身免疫及炎症性疾病等发病机制研究,以及相关疾病的预防、诊断和治疗等技术和产品研发。
附图说明
下面结合附图和具体实施方式对本发明做更进一步的具体说明,本发明的上述和/或其他方面的优点将会变得更加清楚。
图1是HBXIP△LysM鼠的制备方法及基因型鉴定。
图2是HBXIP△LysM鼠BMDM中HBXIP敲除效果的转录水平验证。
图3是HBXIP△LysM鼠BMDM中HBXIP敲除效果的蛋白水平验证。
图4是野生型小鼠(WT)与HBXIP△LysM鼠BMDM中衰老相关基因的表达。
图5是野生型小鼠与HBXIP△LysM鼠血清中衰老相关的分泌表型因子水平。
图6是野生型小鼠与HBXIP△LysM鼠肝功能检测。
图7是野生型小鼠与HBXIP△LysM肾功能检测。
图8是野生型小鼠与HBXIP△LysM组织切片H&E染色。
具体实施方式
下述实施例中所述实验方法,如无特殊说明,均为常规方法;所述试剂和材料,如无特殊说明,均可从商业途径获得。
实施例1:髓系细胞条件性敲除HBXIP小鼠的制备方法及基因型鉴定。
1、实验材料
1.1实验用试剂:SYBR GREEN PCR Master Mix(QPK-201)购于日本TOYOBO公司;主要引物合成于上海捷瑞生物工程有限公司。抗体HBXIP(#14633),β-Actin(#3700),购于CST公司。蛋白酶K(10401ES60)购于翌圣生物科技股份有限公司。鼠尾裂解液(50mL的配方为:1M Tris-Hcl 0.5mL,0.5M EDTA 1mL,10%SDS 2.5mL,5M Nacl 1mL,H2O 41ml,调PH至8.0)。Case9 mRNA购自于Sigma-Aldrich,货号为CAS9MRNA-1EA。
1.2实验用动物及饲养:野生型小鼠、髓系细胞特异性敲除Cre工具鼠(LysMcre/+)、HBXIPfl/+、HBXIPfl/fl、HBXIP△LysM鼠。全价营养颗粒饲料:由江苏省协同医药生物技术有限公司提供;饲养条件:室温20±2℃,湿度55-65%,明暗交替,光度适度,通风洁净良好。
2、实验方法
2.1髓系细胞条件性敲除HBXIP小鼠的制备方法。
(1)骨髓细胞特异性表达Cre重组酶小鼠(LysMcre/+):英文名B6.129P2-Lyz2tm1(cre)Ifo/J,Stock No:004781,购自The Jackson Laboratory。该品系小鼠基因组插入Cre酶基因,并且该基因可以通过骨髓细胞特异性的启动子在骨髓细胞表达Cre重组酶。与loxp转基因小鼠交配,则Cre介导的重组能够将目的基因序列删除,这些序列删除具有细胞特异性,仅在骨髓细胞系中发生,包括单核细胞、成熟的巨噬细胞和粒细胞等。
(2)loxp转基因杂合子(HBXIPfl/+)小鼠的制备:小鼠品系为C57BL/6,在其乙肝病毒X蛋白结合蛋白基因组(NC_000069.7)的第二个外显子(1013-1074)两侧的内含子区域分别添加loxp1位点和loxp2位点,即在HBXIP基因组序列的第762位核苷酸后插入SEQ IDNo.1核苷酸序列(loxp1位点),第1250位核苷酸后插入SEQ ID No.2核苷酸序列(loxp2位点),两个loxp位点的其核苷酸序列分别如SEQ ID No.1和SEQ ID No.2所示。
SEQ ID No.1Loxp1插入位置及序列:
GGAGTTGCAGTCCTAGAGCATGCTTCTATACggtccgctgcagATAACTTCGTATAA TGTATGCTAT ACGAAGTTATgagccgCAAGGACAGAGCCCTAAAGATAACTGC
SEQ ID No.2Loxp2插入位置及序列:
GGCAGAAATGTTCCTCCCAGTTCTAtccgccATAACTTCGTATAATGTATGCTAT ACGAAGTTATggatccgggtcggCTACAACTGTTCCTACTAAAATGGTTTTG。
其中,上述loxp序列的插入方法如下:运用Optimized Cas9/CRISPR System(OCAS)技术,设计了两个gRNA序列,分别是gRNA靶点1:tagagcatgcttctataccaAGG(为基因组的正向序列,gRNA-1,核苷酸序列如SEQ ID No.3所示),gRNA靶点2:GGAACAGTTGTAGAACTGGGAGG(为基因组的反向序列,gRNA-2,核苷酸序列如SEQ ID No.4所示)。通过显微注射,将Case9 mRNA、两个gRNA序列、SSODN同源重组模板(核苷酸序列别如SEQ ID No.5所示)导入小鼠受精卵中,利用DNA修复机制把带有2个loxp的完整序列插入到基因组中去。胚胎体外培养1-2小时后,移植入假孕母鼠的输卵管中,代孕鼠伤口缝合后待产。产仔后,进行F0代验证,小鼠杂交验证等。
(3)交配方法:第一步,将HBXIPfl/+与HBXIPfl/+个体交配,可以获得HBXIPfl/fl纯合子小鼠;第二步,HBXIPfl/fl与LysMcre/+个体交配,可以获得既含有loxp位点又表达Cre酶的个体,即(HBXIPfl/+-LysMcre/+)个体;第三步,(HBXIPfl/+-LysMcre/+)个体再与(HBXIPfl/+-LysMcre/+)个体交配,即可获得(HBXIPfl/fl-LysMcre/+)个体。研究已经证实,loxp位点与Cre酶结合,就会发生基因删除(Clausen et al.,1999)。因此,(HBXIPfl/+-LysMcre/+)个体为骨髓细胞特异性敲除HBXIP基因的杂合子,(HBXIPfl/fl-LysMcre/+)个体则为骨髓细胞特异性敲除HBXIP基因的纯合子(简写为HBXIP△LysM)。
2.2小鼠基因型鉴定。从HBXIP△LysM小鼠剪取0.5cm左右的尾巴,加入鼠尾裂解液和蛋白酶K(500μl,体积比为100:1),55℃摇动消化过夜。消化完全后,5000r,离心3min,取200μl上清置于干净EP管中。在上清中加入400μl无水乙醇,上下颠倒混匀,此时可见絮状DNA沉淀。12000r离心5min,弃去上清。在沉淀中加入400μl 70%乙醇,混匀,12000r离心5min,弃去上清。放在超净台晾干,加入200μl ddH2O溶解备用。PCR法检测相关基因的表达。
loxp小鼠鼠尾鉴定的引物如下:
F:CACTTTCACGCACATCTTCCCGC
R:CAGGCACCTCTGCTTCACAAAGACAC
HBXIPfl/+=296bp和348bp
HBXIPfl/fl=348bp
WT=296bp
Cre小鼠鼠尾鉴定的引物如下:
F:CTTGGGCTGCCAGAATTTCTC
R1:CCAGAAATGCCAGATTACG
R2:TTACAGTCGGCCAGGCTGAC
Mutant=750bp
Heterozygote=300bp和750bp
WT=300bp
2.3小鼠BMDMs的提取、分离与培养。取野生型小鼠C57BL/6和HBXIP△LysM小鼠的腿骨,PBS冲出骨髓,裂解红细胞,DMEM培养基(10vt%FBS(胎牛血清),小鼠M-CSF(巨噬细胞集落刺激因子)25ng/ml)培养3天,待多数细胞贴壁,更换新鲜培养基,再培养3天,约6天左右BMDMs分化为M0型。
2.4实时定量PCR法验证HBXIP△LysM小鼠BMDM中HBXIP敲除效果。提取小鼠BMDM的总RNA并进行反转录,制备成cDNA。使用SYBR Green PCR Master Mix进行实时定量PCR检测,β-actin为内参,用2-△△Ct法计算mRNA的相对表达水平。
2.5蛋白免疫印迹法验证HBXIP△LysM小鼠BMDM中HBXIP敲除效果。裂解小鼠BMDM,BCA定量试剂盒测定蛋白浓度;按40μg的总蛋白上样量,依次进行电泳、转膜、封闭、一抗孵育、二抗孵育、显色、曝光。
3、实验结果
3.1 HBXIP△LysM小鼠鼠尾基因型鉴定结果。通过2.1所述的繁育方式(图1左),得几种不同基因型的小鼠。根据loxp与Cre重组酶的敲除原理,经鼠尾鉴定,只要在基因组DNA中检测loxp位点和Cre重组酶基因的有无就可判断幼鼠的基因型。如实施例1的2.1和图1右所示,若用loxp引物进行扩增:HBXIPfl/+=296bp和348bp;HBXIPfl/fl=348bp;WT=296bp。若用Cre引物进行扩增:Mutant=750bp;Heterozygote=300bp和750bp;WT=300bp。若用loxp小鼠鼠尾鉴定的引物扩增出348bp条带,同时用Cre小鼠鼠尾鉴定的引物扩增出750bp条带的小鼠则为HBXIP△LysM小鼠。
3.2 HBXIP△LysM小鼠BMDM中HBXIP敲除效果验证。收取BMDMs细胞,分别进行RNA提取和蛋白提取。结果显示,与野生型小鼠相比,HBXIP△LysM小鼠BMDM中不表达HBXIP的蛋白(图2),其转录水平也显著下调(图3),证明BMDM中HBXIP的敲除效果显著。
实施例2:髓系细胞条件性敲除HBXIP小鼠早衰模型的表型验证。
1、实验材料
1.1实验用试剂:实时定量PCR所需试剂同实施例1中的1.1所述。ELISA检测试剂盒购于联科生物,谷丙转氨酶活性检测试剂盒(BC1555)、谷草转氨酶活性检测试剂盒(BC1565)、Bradford蛋白浓度定量试剂盒购(PC0010)自北京索莱宝科技有限公司。
1.2实验用动物及饲养:野生型小鼠与HBXIP△LysM鼠,7-8月龄。全价营养颗粒饲料:由江苏省协同医药生物技术有限公司提供;饲养条件:室温20±2℃,湿度55-65%,明暗交替,光度适度,通风洁净良好。
2、实验方法
2.1实时定量PCR法检测野生型小鼠与HBXIP△LysM鼠BMDM中衰老相关基因的表达。实时定量PCR的检测方法同实施例1中2.2。
2.2 ELISA法检测野生型小鼠与HBXIP△LysM鼠血清中衰老相关的分泌表型因子水平。根据细胞因子检测试剂盒的说明书,用ELISA的实验方法,测定小鼠血清中衰老相关的分泌表型因子水平。依次进行浸泡酶标板、加标准品、加样本、孵育、洗涤、加酶孵育、洗涤、加底物显色、加终止液、检测读数。检测读数应在30分钟之内,使用酶标仪进行双波长检测,测定450nm最大吸收波长和570nm或630nm参考波长下的OD值。校准后的OD值为450nm的测定值减去570nm或630nm的测定值。
2.3小鼠血清中谷丙、谷草转氨酶的活性检测。谷丙转氨酶(ALT)活性检测:首先将丙氨酸标准品用蒸馏水稀释至2μmol/mL,将标准品稀释为1.5,1,0.8,0.6,0.4,0.2,0.1,0.05,0mM等浓度梯度。在标准管、测定管、对照管中分别加入一定体积的丙氨酸(200mM),α-酮戊二酸溶液(2mM)和2,4-二硝基苯肼溶液。按血清体积计算,ALT活力单位:每小时每mL血清样本催化产生1μmol丙酮酸的量为一个活力单位。谷草转氨酶(AST)活性检测:首先将丙酮酸钠标准品用蒸馏水稀释至2μmol/mL,将标准品稀释为1.5,1,0.8,0.6,0.4,0.2,0.1,0.05,0mM等浓度梯度。在标准管、测定管、对照管中分别加入一定体积的化α-酮戊二酸(2mM)、天门冬氨酸(200mM)和2,4-二硝基苯肼溶液。按血清体积计算,AST活力单位:每小时每mL血清样本催化产生1μmol丙酮酸的量为一个活力单位。
2.4Bradford法检测小鼠尿蛋白浓度。完全溶解蛋白标准品,使终浓度为0.2mg/ml。将标准品按0,2,4,6,8,12,16,20微升分别加到96孔板中,加PBS稀释液补足到20微升。将小鼠尿液样品作适当稀释(2倍、4倍、8倍稀释),加20微升到96孔板的样品孔中。各孔加入200微升稀释后的1×G250考马斯亮蓝染色液,室温放置3-5分钟。用酶标仪测定A595。根据标准曲线计算出样品中的蛋白浓度。
3、实验结果
3.1野生型小鼠与HBXIP△LysM鼠BMDM中衰老相关基因的表达。提取小鼠BMDMs(8个月龄)中的RNA,并进行发转录。实时定量方法检测野生型小鼠与HBXIP△LysM鼠BMDM中衰老相关基因的表达。结果显示,HBXIP△LysM鼠BMDM中衰老相关基因p16,p21,MCP-1,IL-6,TNF-α,IL-1β的表达水平显著升高(图4)。
3.2野生型小鼠与HBXIP△LysM鼠血清中衰老相关的分泌表型因子水平。收集野生型小鼠与HBXIP△LysM鼠(8个月龄)的血清,ELISA法检测血清中衰老相关的分泌表型因子水平。结果显示,HBXIP△LysM鼠血清中衰老相关的分泌表型因子水平IL-6,TNF-α,IL-1β显著升高(图5)。
3.3野生型小鼠与HBXIP△LysM鼠肝、肾功能检测。收集野生型小鼠与HBXIP△LysM鼠(8个月龄)的血清,分别用谷丙转氨酶(ALT)活性和谷草转氨酶(AST)活性检测试剂盒检测小鼠肝脏功能。结果显示,HBXIP△LysM鼠血清中谷草转氨酶活性显著高于野生型小鼠,其谷丙转氨酶活性与野生型小鼠相比,无显著性差异(图6)。收集野生型小鼠与HBXIP△LysM鼠的尿液,Bradford法检测尿液中的蛋白浓度。结果显示,HBXIP△LysM鼠尿液中的蛋白浓度显著高于野生型小鼠(图7)。另外,对野生型小鼠与HBXIP△LysM鼠的皮肤、肺、肝脏、肾脏的组织切片进行H&E染色,结果显示HBXIP△LysM鼠毛囊萎缩,肺部有大量炎性细胞浸润,肝肾组织结构改变等(图8)。以上实验结果表明,HBXIP△LysM鼠出现了衰老小鼠的症状,即肝肾功能损伤。
本发明提供了一种小鼠早衰模型及其构建方法与应用的思路及方法,具体实现该技术方案的方法和途径很多,以上所述仅是本发明的优选实施方式。应当指出,对于本技术领域的普通技术人员来说,在不脱离本发明原理的前提下,还可以做出若干改进和拓展其应用,这些改进和应用也应视为本发明的保护范围。本实施例中未明确的各组成部分均可用现有技术加以实现。
序列表
<110> 浙江树人大学
<120> 一种小鼠早衰模型及其构建方法与应用
<160> 5
<170> SIPOSequenceListing 1.0
<210> 1
<211> 110
<212> DNA
<213> loxp1
<400> 1
ggagttgcag tcctagagca tgcttctata cggtccgctg cagataactt cgtataatgt 60
atgctatacg aagttatgag ccgcaaggac agagccctaa agataactgc 110
<210> 2
<211> 107
<212> DNA
<213> loxp2
<400> 2
ggcagaaatg ttcctcccag ttctatccgc cataacttcg tataatgtat gctatacgaa 60
gttatggatc cgggtcggct acaactgttc ctactaaaat ggttttg 107
<210> 3
<211> 23
<212> DNA
<213> gRNA-1
<400> 3
tagagcatgc ttctatacca agg 23
<210> 4
<211> 23
<212> DNA
<213> gRNA-2
<400> 4
ggaacagttg tagaactggg agg 23
<210> 5
<211> 3401
<212> DNA
<213> SSODN
<400> 5
gaaaaggaga aggagaccaa aatgtctgga ttctatagaa aggagcccta tagaaaggga 60
agggcagccc agcccctggg ctggaaagtt cagggttggg ggcaaggtat gccaggtggg 120
aactgaggga tgcagaacct ggaggccagt tctgctttga taggtaaagt atacacctca 180
gcctcttgac ctagggtcag aaactgagca ctgtcttctt agcgattggc ctattgcata 240
gatgagacca tgccagacct gctggttact ttaaaattta aaccaggtct acgtctggtt 300
aggactggaa attgcttgaa ccaaatccaa aggttaaaaa tcactaagtc caagtgctag 360
gtcaggaaaa ggccctgagg cccgactaca gattgctttg aaggcccagc acccccaatc 420
gaaagccagc catcactggt cctgtggtag tagctatgcc ttttcgtaaa gagcgcggac 480
gcggcgccgc gctgaatttc gtccctctgg agacgccgtc caggcgcccg cctcggtcaa 540
gtcacgtgat cgaggtttgc ggtgaaggag gaagtgtttt gctgcggggt cctggcctgg 600
ggcggacagc ctgcgggatg gaggcgactt tggagcagca tttggaggac acgtgagtag 660
tgcgtgcggc cggtcctggg ctccggacag gggagctgga atgggacagc ggcatggacc 720
gcgagtgtct gcggaagcgt ttggggcact cggggcggcg agcgggtgac ttctgcctac 780
ggccgggccg ctcgttactg ggtagtaaag tttcgttagg cgtgttcgca gaatcgagta 840
gctcttgaga agtttgggaa acggattaag tttggggaag gatgccccgg gtgtgctaaa 900
tcgagccccc gcagtgccaa agcactttca cgcacatctt cccgcgtttg tggcccgtca 960
gttgctcagc gcttgtgaag taaatatatc cgtaaagttt ttcagctatc tctgtaaaat 1020
ttaaaattgg gaggtgtaaa gtggcttaca agaagacacc tcctccttga gcttcttaat 1080
cccctccagg agcaattccc gttactgaga tttaacagtt gtcttcagga gttgcagtcc 1140
tagagcatgc ttctatacgg tccgctgcag ataacttcgt ataatgtatg ctatacgaag 1200
ttatgagccg caaggacaga gccctaaaga taactgcctt gtttgtgtct ttgtgaagca 1260
gaggtgcctg agaaaatggt ttgggttttg ttttgtttat ttaaacaact cacagtttgt 1320
cctctgaaag ggggcgaaaa aatttaaggg ctgatttgaa gtgcttaata ctcggtgcat 1380
agaaaatctg ttttactaca gtaatttgaa atattttctt cacatcatct ggttcatctt 1440
tcttgtgctc ccaaaattag aatgaagaat ccatccattg ttggagtcct atgcacagat 1500
tcacaaggac ttaatctggg ctgtaagtgt ctcctaccag cctccctttg aagttctgag 1560
agccttaact tacactgcta ctattttcta gcttttattc ctgttacctt tagggcatag 1620
agactatctc caagtaagag tagatggttg aagcctttca gttgcatttt aaaggcagaa 1680
atgttcctcc cagttctatc cgccataact tcgtataatg tatgctatac gaagttatgg 1740
atccgggtcg gctacaactg ttcctactaa aatggttttg aataaatttt aagtggtcta 1800
gaaaagggct ttagataagg acatctttac tgaatgcatt ccctgtgcag gcacagtcag 1860
gctacactat ttccttaatt gcctcaataa ccctgaaaat ggatgatgct ggctgctagt 1920
ccagccactc tcaacagtaa gttattgtca gtaaaaatag ggatttccta gttagacacg 1980
tctgacttca accccattct ccgatgctgt ctgctagcaa catgagtgcc gaacagaagg 2040
agcctcttgg ggcttcagtt tcttcattgg gttattttat ttcatacata cattatgtgt 2100
gtgttgtctt aagacatttt tttttaaaaa cttattctac gtggccctgg ctgtcctgga 2160
acaaactttg tagaccatgc tggcctgtaa ctcacagaga tctgcctgcc tctatccctt 2220
gaatgctggg aacaaaggtg tgcatcacca tgcccagcca ggcactattc ttagtgtttt 2280
cattataaaa cgtacataac cccccttcct gccccccccc ccccaccaaa gccctttatg 2340
gtcaagaaat ttagcaagct taaaagtacc ttgcccaggg tcaaacacct aatgaatggt 2400
tgagatagga tgtttttaaa gctggctcca aagcttaaaa cacccagtac agaaccaaga 2460
tgtgtttgtg tggtgttcaa taaattgtag caattacaga taaggaacta agtccagaaa 2520
ggtaaatagc taaagttaat taatgtcaga aactagtaaa cccaagaatc cttataactg 2580
atgcaggttt tttagagctc tgatcttttg ctggtatgat acctgacaaa agtaatatag 2640
ttatgtctta tacaaaaagc agccatttgg aacaaaggta aatttttttg aagcatttgc 2700
caagttacta atgaaaactc tttaaatgca aatgtggagg aaaaaaaaaa actaagtaaa 2760
accttcaagg tgcgaagttg ctatttccaa tagatttccg ggctgcactt tggcctacgg 2820
attttttatg tagtaatagt caatccagaa tttctgccag gttatattgt ctactacctt 2880
agttttaggt gtaagtaaac ccctttattt cagggatcta taataagctt ggtggttacc 2940
ttttgtgcct agagcctgtt agttaataca agtcaaagta atagtaaaga ctcgggggac 3000
atttgaaagg agcccagcta gcttctgcta gcagaaatag ttgctcacag gtcttcacat 3060
atgctggcaa ggtgatctta caactggact tctgagtaat ggctgcttct ttgagattga 3120
gcataggaag agaaactcag atttcccata aggaattaat tagcatcaac aagcccctta 3180
tccatactga atgctttttg tcactctcgc ctttgaattt cttggtttca gcaaggttcc 3240
tataaaatag ttactaccat cagatgactt gaattacagc ttccttatat gcttgagaag 3300
gtgtttagag atagtgaggg gaataactct gaaaactaca tgtcgtttac gactttgctg 3360
atttaagaac aattgccagg ctttctcact aatggactca g 3401
Claims (10)
1.一种小鼠早衰模型,其特征在于,敲除小鼠骨髓来源细胞中的乙肝病毒X蛋白结合蛋白。
2.根据权利要求1所述小鼠早衰模型,其特征在于,所述敲除为敲除乙肝病毒X蛋白结合蛋白编码基因中的第二个外显子。
3.根据权利要求2所述小鼠早衰模型,其特征在于,所述乙肝病毒X蛋白结合蛋白编码基因的mRNA序列为Gene Bank中的Accession:NM_026774.2,其基因组序列为Gene Bank中的Accession:NC_000069.7。
4.根据权利要求1所述小鼠早衰模型,其特征在于,所述敲除为通过Cre-loxp系统敲除。
5.根据权利要求1所述小鼠早衰模型,其特征在于,所述敲除为通过骨髓细胞特异性表达Cre重组酶小鼠LysMcre/+敲除。
6.权利要求1-5中任意一项所述小鼠早衰模型的构建方法,其特征在于,包括如下步骤:
(1)将HBXIPfl/+小鼠与HBXIPfl/+小鼠交配,获得HBXIPfl/fl纯合子小鼠;
(2)将HBXIPfl/fl小鼠与LysMcre/+小鼠交配,获得BXIPfl/+-LysMcre/+小鼠;
(3)将HBXIPfl/+-LysMcre/+小鼠与HBXIPfl/+-LysMcre/+小鼠交配,获得HBXIPfl/fl-LysMcre/+小鼠。
7.根据权利要求6所述方法,其特征在于,步骤(1)中,所述HBXIPfl/+小鼠为将C57BL/6小鼠中乙肝病毒X蛋白结合蛋白基因组序列的第762位核苷酸后插入如SEQ ID No.1所示的核苷酸序列,第1250位核苷酸后插入如SEQ ID No.2所示的核苷酸序列。
8.权利要求1-5中任意一项所述小鼠早衰模型在开发或筛选预防和/或治疗早衰产品中的应用。
9.权利要求1-5中任意一项所述小鼠早衰模型在开发或筛选预防和/或治疗早衰技术方法中的应用。
10.权利要求1-5中任意一项所述小鼠早衰模型在早衰研究中的应用。
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110842679.9A CN113528572B (zh) | 2021-07-26 | 2021-07-26 | 一种小鼠早衰模型及其构建方法与应用 |
PCT/CN2021/110471 WO2023004847A1 (zh) | 2021-07-26 | 2021-08-04 | 一种小鼠早衰模型及其构建方法与应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110842679.9A CN113528572B (zh) | 2021-07-26 | 2021-07-26 | 一种小鼠早衰模型及其构建方法与应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113528572A true CN113528572A (zh) | 2021-10-22 |
CN113528572B CN113528572B (zh) | 2023-06-20 |
Family
ID=78121336
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110842679.9A Active CN113528572B (zh) | 2021-07-26 | 2021-07-26 | 一种小鼠早衰模型及其构建方法与应用 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN113528572B (zh) |
WO (1) | WO2023004847A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114107272A (zh) * | 2021-12-15 | 2022-03-01 | 徐州医科大学 | mPGES-2作为预防和/或治疗衰老疾病的药物靶点的应用 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117587069A (zh) * | 2024-01-18 | 2024-02-23 | 鹏澄健康(北京)科技有限公司 | 一种通用型溶酶体贮积症肌骨骼病变动物模型及构建方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2015012808A (ja) * | 2013-07-03 | 2015-01-22 | 村田 亮 | Stam1ノックアウト老化促進モデルマウス |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8198253B2 (en) * | 2006-07-19 | 2012-06-12 | Isis Pharmaceuticals, Inc. | Compositions and their uses directed to HBXIP |
WO2013106662A1 (en) * | 2012-01-13 | 2013-07-18 | Advanced Genomic Technology, Llc | Transgeneic non-human animal model for accelerated aging and/or age-related symptom, and use thereof |
CN108409835B (zh) * | 2018-02-28 | 2021-09-14 | 河北科技大学 | 一种拮抗乙肝病毒x蛋白结合蛋白的多肽、包含该多肽的药物及其应用 |
-
2021
- 2021-07-26 CN CN202110842679.9A patent/CN113528572B/zh active Active
- 2021-08-04 WO PCT/CN2021/110471 patent/WO2023004847A1/zh active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2015012808A (ja) * | 2013-07-03 | 2015-01-22 | 村田 亮 | Stam1ノックアウト老化促進モデルマウス |
Non-Patent Citations (4)
Title |
---|
FENG-ZE WANG, ET AL.: "Promotion of cell proliferation by HBXIP via upregulation of human telomerase reverse transcriptase in human mesenchymal stem cells", 《ACTA PHARMACOL SIN》 * |
SHI HUI, ET AL.: "Hepatitis B X-interacting Protein Restrains Hepatic Gluconeogenesis Through Suppressing The Expression of PEPCK", 《PROGRESS IN BIOCHEMISTRY AND BIOPHYSICS》 * |
孔维健等: "基于Cre-Loxp系统条件性基因敲除小鼠的构建及其应用进展", 《中国实验诊断学》 * |
王小双等: "生长激素受体基因敲除小鼠模型", 《中国实验动物学报》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114107272A (zh) * | 2021-12-15 | 2022-03-01 | 徐州医科大学 | mPGES-2作为预防和/或治疗衰老疾病的药物靶点的应用 |
CN114107272B (zh) * | 2021-12-15 | 2022-06-24 | 徐州医科大学 | mPGES-2作为靶点在开发或筛选或制备用于预防和/或治疗衰老疾病的药物中的应用 |
Also Published As
Publication number | Publication date |
---|---|
WO2023004847A1 (zh) | 2023-02-02 |
CN113528572B (zh) | 2023-06-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN113528572B (zh) | 一种小鼠早衰模型及其构建方法与应用 | |
CN107815467A (zh) | 人源化基因改造动物模型的制备方法及应用 | |
Hasegawa et al. | Generation of CRISPR/Cas9-mediated bicistronic knock-in ins1-cre driver mice | |
CN107072217A (zh) | 长寿动物模型和延长寿命与抑制肿瘤发生的方法 | |
EP3420811A1 (en) | Non-human model for neurofibromatosis type 1 | |
EP2842417B1 (en) | Urokinase-type plasminogen activator transgenic mouse | |
Li et al. | A Bama miniature pig model of monoallelic TSC1 mutation for human tuberous sclerosis complex | |
WO2021057806A1 (zh) | 糖尿病疾病模型犬的建立方法 | |
EP1670308B1 (en) | Chimeric cancer models | |
CN110691512B (zh) | 遗传工程化的非人类哺乳动物及其构建方法和应用 | |
Duo et al. | Single-base editing in IGF2 improves meat production and intramuscular fat deposition in Liang Guang Small Spotted pigs | |
US20030028910A1 (en) | Non-human transgenic animal whose germ cells and somatic cells contain a knockout mutation in DNA encoding orphan nuclear receptor ERRalpha | |
CN110846321B (zh) | 一种突变基因及其用于构建斑色鱼鳞癣小型猪模型的用途 | |
CN112626122A (zh) | hKDR人源化小鼠模型及其建立方法和应用 | |
Schook et al. | DNA-based animal models of human disease: from genotype to phenotype | |
CN111808859B (zh) | WAS基因的gRNA及其应用 | |
CN114045290B (zh) | 角朊蛋白基因修饰小鼠动物模型的构建方法和应用 | |
CN113652448B (zh) | 构建Tp53基因敲除金黄叙利亚仓鼠模型的方法和应用 | |
CN116042714A (zh) | 一种mettl7b基因肺部特异性敲入小鼠模型的构建方法及其应用 | |
CN114982718B (zh) | 一种基因缺陷导致的小鼠全身性肥胖模型及其构建方法 | |
CN118140873A (zh) | 糖尿病动物模型及其构建方法和应用 | |
CN118773300A (zh) | Rcan2基因在2型糖尿病中的应用 | |
CN114958917A (zh) | 一种克罗恩病小鼠动物模型的构建方法和应用 | |
CN116999543A (zh) | Virma蛋白在制备调控神经系统早期发育功能的药物中的应用 | |
CN118326026A (zh) | 一种黏连蛋白病诊断标志物及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |